Startup Companies
AIVF
AiVF is a medical technology company empowering fertility clinic with artificial intelligence to help improve treatment efficiency, efficacy, and quality of care. The CE-marked EMA SaaS platform is operational and helping clinics perform analyses of embryo quality and potential for viable pregnancy, while optimizing operational efficiencies.
The multidisciplinary team of physicians, embryologists, data scientists and experts in computer vision, machine learning and AI are focused on bringing data-driven processes to all phases of the fertility journey for clinics and parents-to-be.
AIVF is headquartered in Tel Aviv, Israel. Follow us on Facebook, Instagram, LinkedIn and Twitter or visit aivf.co for more information.
Amplexa Genetics
Founded in 2006, Amplexa Genetics is one of the world’s longest-existing private genetic laboratories and among the pioneers in the sale of genetic analyses. We focus on high quality and usability in our work.
Our mission is to provide knowledge that can help private individuals and professionals make important decisions about health.
Our vision is to develop our position as an internationally recognized partner and supplier of applicable genetic analyses.
Together with recognized and respected scientific experts we have developed more than 100 different clinical genetic tests.
The tests cover recessive screening and preimplantation genetic testing for the fertility segment as well as highly significant disease-causing genes for the clinical genetics segment.
Amplexa Genetics has a strong network of specialists with competencies in genetics and genetic research.
We use the best and latest technologies in the field with an updated fleet of machines.
Baibys
AI and robotics-based autonomous sperm selection for IVF
BAIBYS’ autonomous sperm selection solution for In-Vitro Fertilization (IVF) is designed to analyze living sperm cells in real-time using Machine Vision (MV) and Artificial Intelligence (AI).
BAIBYS’ system evaluates the cells according to morphological criteria, which can only be identified using high magnification.
The system recognizes structures in motion in order to evaluate the quality of living sperm cells according to previously established criteria using state-of-the-art AI algorithms.
It then autonomously selects and collects the sperm with the highest fertilization potential to microinject into the egg in IVF procedures.
Béa Fertility
Béa is building the first clinical grade intracervical insemination kit designed for home use.
Fairtility
Fairtility is powering in vitro fertilization (IVF) through transparent AI to improve outcomes. Equipping clinicians and their patients with unparalleled visibility into IVF treatment, CHLOE™ (Cultivating Human Life through Optimal Embryos) is the first and only transparent AI-based decision support tool that provides clinicians with complete visibility into the clinical and laboratory parameters that make up data output to help improve IVF outcomes.
CHLOE’s end-to-end, flexible, and transparent-AI-powered decision support tool, aims to augment clinical decision making, leading to more personalized treatment decisions with the goal of achieving consistently higher positive outcomes. Beginning with CHLOE EQ™, a proprietary embryo selection grading platform, Fairtility is on a path to expand CHLOE’s application to support the full IVF journey.
Fairtility is on a mission to transform IVF into a transparent process, delivering unparalleled visibility to both clinicians and patients with CHLOE™, and empowering prospective parents to have meaningful discussions with their clinicians and embryologists and make informed decisions together throughout their IVF journey. To learn more about Fairtility or schedule a demo, visit our website and follow us on Twitter and LinkedIn.
Fertigo Medica
Fertigo Medical Ltd. is a next generation femtech company based near Haifa, Israel.
We pioneer AI powered, personalized medicine solutions for the global fertility market, and for in-vitro fertilization (IVF) patients specifically.
Our expertise in IVF begins with the predictive power of Endometrial Dating, namely the determination of the uterus evolutionary stage during a menstrual cycle.
Fertigo developed an innovative mini-hysteroscope in order to get access to the endometrium morphological parameters. Then, by our AI-powered, sophisticated analysis, we are able to follow the endometrium changes in the course of the woman’s monthly cycle. This allows an accurate prediction of the optimal embryo transfer timing and in turn, an increase in the IVF success rate.
FertilAI
FertilAI is a med-tech company based in Israel which aims to empower fertility clinics and OBGYN’s by providing the Fertilane platform.
The platform consists of patient and doctor applications that automate the operational workflow in fertility clinics and provide algorithms for decision support / full automation of clinical decisions.
The algorithms assist doctors by reducing their workload, increasing success rates, and reducing unnecessary tests.
Our first algorithm for fully managing Frozen Embryo Transfer / Intrauterine Insemination / Ovulation Tracking is currently in the validation phase and is showing very promising results. The Fertilane platform is currently being deployed in one of the largest IVF clinics in the world and is estimated to treat over 10,000 cycles by the end of the year.
Follow us on linkedin or www.fertilAI.com for more information.
Fertilis
- Founded: December 2019
- Location: Adelaide, South Australia, AUSTRALIA
- Founders: Marty Gauvin CEO; Prof Jeremy Thompson CSO
- Employee number: 1-10 employees
- Last Funding Type: Seed $AUD2.75M
- Legal Name: Fertilis Pty Ltd
- Company Type: Medical device manufacturer
- Contact Email [email protected]
- Website: fertil.is
Ferty U
«SERVICE FOR OVARIAN RESPONSE PREDICTION IN IVF INFERTILITY TREATMENT» is software for doctors that works discretely and as integration with other software. The problems we cope with are as follows: insufficient predictability of ovarian response and related problems such as risks, costs and availability of IVF treatment. Number of retrieved oocytes is the factor that influences treatment success. Our solution is based on ML. Machine learning to identify addition predictive factors, make the prognoses more accurate and faster, and predict the number of matured oocytes as well. Service allows make stimulation results more predictable, avoid the start «fail-cycles», carry out part of the treatment remote, increase the availability of the treatment, and reduce patients and insurance company’s costs. Our next step of development is to manage the therapy outcome through modified factors. All participants of IVF treatment will benefit due to high predictability of ovarian response.
Future Fertility
Future Fertility is a Toronto based AI software company specialising in the first available non-invasive image analysis tool for the evaluation of oocytes.
Our current products include Violet and Magenta. The first one is an oocyte prediction report for egg cryopreservation patients, while the second is an egg grading report designed for use during the IVF cycle.
Hertility Health
IMMA
Founded by doctors & engineers, IMMA is a women-led Israeli company, building the best comprehensive solution for transvaginal scans from home.
Combining a personal ultra-portable automated transvaginal ultrasound medical device and an AI powered platform, IMMA will enable women to perform their own transvaginal scans by themselves. IMMA offers women the opportunity to take back the control of their life during their fertility treatment, but also throughout different life stages, leading to better results and better prevention, at a lower cost, focusing on accessibility and autonomy.
“Her health, in her hands”, literally.
IVF 2.0 Ltd
Supporting bench-side decisions in the IVF process with data-driven solutions to improve patients’ outcomes.
Maia Fertility
Maia Fertility is an Israeli-based company addressing one of the biggest unmet needs in reproductive health.
In the ever-developing reproductive health ecosystem, one of the key challenges remains the low rate of embryo implantation to the uterus.
Maia Fertility has a first-in-class biological drug-based product, Fertizime™, to enhance embryo implantation Fertizime™ was discovered in Weizmann institute in Prof. Irit Sagi`s lab and is very effective in increasing embryo implantation and birth rate. Fertizime™ has many advantages, among others safety, efficacy, and the capability to be effective cross-species which allow the expansion into several markets.
The company has already validated the technology in various animal models and is ramping up efforts to reach the fertility markets which are estimated to be in the range of $4B-$6B.
MIM Solutions
Originating from the University of Warsaw, MIM Solutions is a leading Polish Machine Learning Company.
At MIM Solutions, we are committed to combining rigorous scientific research with solutions to real-world problems. We provide organizations with the most efficient and, at the same time, the safest ML technology, remaining at the forefront of scientific research in this field. In particular, we build prediction and recommendation systems. We run ambitious research and development projects for MedTech. Founder-led and with the majority of PhDs, we have one of the most experienced teams of AI and ML specialists in Poland.
Ovaterra
QART Medical
QART Medical is a clinical-stage MedTech founded in 2018, addressing the global infertility epidemic and in particular, male factor infertility. The company develops breakthrough solutions for highly informative characterization and selection of individual sperm cells for in-vitro fertilization (IVF), aiming to improve upon current standards in the Assisted Reproductive Technology (ART) market.The company brings together a strong and experienced team of > 10 employees with diverse expertise in medical engineering technology, clinical embryology, business development, clinical affairs and software and algorithms development, to address the various requirements of developing a medical device.The QART product, called QISI™ – quantitative interferometric sperm imager – is based on clinically-adapted Interferometric Phase Microscopy (IPM) technology, which allows for holographic imaging of biological specimens. This powerful technology was developed and adapted to an operator-friendly, resource-friendly and clinical-lab-adapted compact portable interfermetric device by Prof. Natan T. Shaked in Tel Aviv University, through over seven years of scientific and technological R&D. The core technology of the QART system is protected by a rigorous patent portfolio owned by Prof. Natan T. Shaked.
Stochastic Research
Stochastic Research Technologies (SRT) LLC is a software company that provides solutions to chemical, pharmaceutical, and biomedical problems with modeling, optimization, and control of the process. Stochastic Research also manages Vishwamitra Research Institute, a non-profit organization that engages in fundamental and applied research in algorithms, methods, and tools, energy and environment, sustainability, molecular modeling, process management, supply chain management, and biomedical engineering. In IVF, SRT has developed a pioneering decision support tool called OPTIVF.